Fig. 2: ɑGD2 DCP-IL-12/EVIR unleash ɑPD-1 efficacy in B16F10-OVA/GD2 melanoma. | Nature Communications

Fig. 2: ɑGD2 DCP-IL-12/EVIR unleash ɑPD-1 efficacy in B16F10-OVA/GD2 melanoma.

From: Dendritic cell progenitors engineered to express extracellular-vesicle–internalizing receptors enhance cancer immunotherapy in mouse models

Fig. 2: ɑGD2 DCP-IL-12/EVIR unleash ɑPD-1 efficacy in B16F10-OVA/GD2 melanoma.The alternative text for this image may have been generated using AI.

a Procedure to study engineered DCPs plus ɑPD-1 in female tumour-bearing mice. b Volume of B16F10-OVA/GD2 tumours (mean ± s.e.m.; n = 9). Statistical analysis by two-way ANOVA with Tukey’s multiple comparison test. c Frequency of the indicated immune cells in B16F10-OVA/GD2 tumours (mean ± s.e.m.; n = 9). Statistical analysis by one-way ANOVA with Tukey’s multiple comparison test. d Procedure to study engineered DCPs plus ɑPD-1 in female tumour-bearing mice. e Volume of B16F10-OVA/GD2 tumours (mean ± s.e.m.; DCP-IL-12/CtrlR + IgG, n = 10, except n = 9 at the last timepoint; other groups, n = 10). Statistical analysis by two-way ANOVA with Tukey’s multiple comparison test. f Procedure to study the effects of CD8+ T cell depletion in female tumour-bearing mice. g Frequency of CD8β+ T cells in B16F10-OVA/GD2 tumours (mean ± s.e.m.; DCP-IL-12/EVIR + ɑPD-1, n = 6; other groups, n = 8). Data points in brown, also indicated by an arrow, identify mice with unsuccessful CD8+ T cell depletion. The mice in the PBS group were terminated on day 14, whereas those in the other groups were terminated on day 19 (separated by a dotted line). Statistical analysis by one-way ANOVA with Tukey’s multiple comparison test. h Volume of B16F10-OVA/GD2 tumours (mean ± s.e.m.; PBS, n = 8; DCP-IL-12/EVIR + ɑPD-1/CD8a, n = 6; DCP-IL-12/EVIR + ɑPD-1, n = 7). Statistical analysis by two-way ANOVA with Tukey’s multiple comparison test (black p value, comparing all groups until day 14) or Sidak’s multiple comparison test (red p value, comparing DCP-IL-12/EVIR + ɑPD-1 with DCP-IL-12/EVIR + ɑPD-1/ɑCD8a until day 19). The mice with suboptimal CD8+ T cell depletion (see g) were excluded from the analysis. i Frequency of the indicated macrophage states in the tumours (mean ± s.e.m.; DCP-IL-12/EVIR + ɑPD-1, n = 6; other groups, n = 8). Statistical analysis by one-way ANOVA with Tukey’s multiple comparison test. j Pie charts showing the hematopoietic-cell composition of the tumours. The area of each cell population corresponds to the mean percentage value in the total CD45+ cells (DCP-IL-12/EVIR + ɑPD-1, n = 6; other groups, n = 8). Each data point in (c, g, i) represents one tumour from an independent mouse. Each data point in (b, e, h) represents the mean volume of independent tumours. Source data are provided as a Source Data file.

Back to article page